PRESS RELEASE published on 07/08/2024 at 23:15, 2 years 1 month ago Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement Theralase® closes successful Non-Brokered Private Placement offering to fund cancer research and clinical studies. Proceeds to advance Phase II NMIBC study and Rutherrin® development Non-brokered Private Placement Theralase Technologies Inc. Cancer Research Rutherrin® Phase II NMIBC Study
BRIEF published on 06/20/2024 at 13:05, 2 years 1 month ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/20/2024 at 13:05, 2 years 1 month ago Theralase réutilise avec succès des médicaments non anticancéreux pour le traitement du cancer Recherche Préclinique Thérapie Contre Le Cancer Theralase Rutherrin Réutilisation De Médicaments
PRESS RELEASE published on 06/20/2024 at 13:00, 2 years 1 month ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 2 years 1 month ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
BRIEF published on 06/19/2024 at 13:05, 2 years 1 month ago Rutherrin® démontre une réponse complète dans le cancer du poumon au niveau préclinique Theralase Cancer Du Poumon Étude Préclinique Rutherrin Régression Tumorale
PRESS RELEASE published on 06/19/2024 at 13:00, 2 years 1 month ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 2 years 1 month ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
BRIEF published on 06/18/2024 at 13:05, 2 years 1 month ago Rutherrin® améliore l'efficacité de l'immunothérapie dans les études précliniques Theralase® Immunothérapie Traitement Du Cancer Rutherrin® Inhibiteurs De Points De Contrôle
PRESS RELEASE published on 06/18/2024 at 13:00, 2 years 1 month ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
Published on 08/18/2026 at 02:20, 6 hours 57 minutes ago Numerous High-Grade Assays Extend Tolmer Silver Discovery
Published on 08/17/2026 at 22:30, 10 hours 47 minutes ago Matador Technologies Amends Convertible Note Facility to Expand At the Market Capacity and Commit a Fixed Share of Proceeds to Bitcoin
Published on 08/17/2026 at 21:00, 12 hours 17 minutes ago Taranis Announces New Critical Minerals By-Product Findings at the Thor and Ajax Mines
Published on 08/17/2026 at 15:00, 18 hours 17 minutes ago Norsemont Appoints Ariel Tepperman to Its Board
Published on 08/18/2026 at 09:05, 12 minutes ago How to Reduce Household Electricity Bills in Daily Life -- Sunshare Offers a New Solution
Published on 08/18/2026 at 09:05, 12 minutes ago Castrol ON PG25 cooling fluids validated for NVIDIA AI factory and data centre infrastructure
Published on 08/18/2026 at 09:00, 17 minutes ago Municipality Finance issues a SEK 1,25 billion tap under its MTN programme
Published on 08/18/2026 at 09:00, 17 minutes ago Original-Research: Readcrest Capital AG (von NuWays AG): BUY
Published on 08/17/2026 at 19:45, 13 hours 32 minutes ago Aéroports de Paris S.A - July 2026 traffic figures
Published on 08/17/2026 at 19:45, 13 hours 32 minutes ago Aéroports de Paris S.A - Trafic du mois de juillet 2026
Published on 08/17/2026 at 17:45, 15 hours 32 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 08/17/2026 at 17:40, 15 hours 37 minutes ago Infotel : Déclaration des transactions sur actions propres réalisées du 10 au 14 août 2026 dans le cadre du programme de rachat d’actions.
